Find a Product

Dasatinib

Dasatinib (Sprycel, BMS-354825) is an oral BCR-ABL, c-KIT, SRC inhibitor (IC50=<1, 79, and 0.8, respectively) and cancer drug developed by Bristol-Myers Squibb. FDA approved for treatment of chronic myelogenous leukemia (CML) and philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Catalog No. Size Price Quantity
92-1183 10 mg $89.00

For account specific pricing, please contact Customer Service at customerservicedrx@eurofins.com.
Description
Dasatinib
Compound Type
Agonist
Storage
≤ -20◦C
Source
Synthetic
Cells were plated in a 384-well plate and incubated overnight at 37°C/5% CO₂ to allow the cells to attach and grow. Cells were then stimulated with a control compound, using the assay conditions described below. Following treatment, signal was detected using the InCELL Hunter Detection Kit according to the recommended protocol.